ConforMIS Inc (CFMS) Given Average Recommendation of “Hold” by Analysts

ConforMIS Inc (NASDAQ:CFMS) has earned an average rating of “Hold” from the eight analysts that are presently covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the company. The average 1 year target price among brokers that have covered the stock in the last year is $5.70.

CFMS has been the subject of a number of research reports. BTIG Research upgraded shares of ConforMIS from a “neutral” rating to a “buy” rating and set a $4.00 price target for the company in a report on Wednesday, December 20th. JPMorgan Chase & Co. cut shares of ConforMIS from a “neutral” rating to an “underweight” rating in a report on Tuesday, January 2nd. Finally, Zacks Investment Research cut shares of ConforMIS from a “buy” rating to a “hold” rating in a report on Tuesday, October 31st.

In other news, insider David Cerveny sold 16,392 shares of ConforMIS stock in a transaction dated Wednesday, November 15th. The shares were sold at an average price of $3.17, for a total transaction of $51,962.64. Following the completion of the transaction, the insider now directly owns 151,408 shares in the company, valued at $479,963.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Paul S. Weiner sold 17,723 shares of ConforMIS stock in a transaction dated Wednesday, November 15th. The shares were sold at an average price of $3.17, for a total transaction of $56,181.91. Following the transaction, the chief financial officer now owns 162,009 shares of the company’s stock, valued at $513,568.53. The disclosure for this sale can be found here. Insiders sold 83,248 shares of company stock valued at $235,021 over the last 90 days. Corporate insiders own 9.55% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of CFMS. Rhumbline Advisers grew its holdings in shares of ConforMIS by 21.8% during the second quarter. Rhumbline Advisers now owns 44,782 shares of the medical instruments supplier’s stock valued at $192,000 after buying an additional 8,017 shares during the last quarter. Bank of New York Mellon Corp lifted its position in shares of ConforMIS by 35.6% during the second quarter. Bank of New York Mellon Corp now owns 171,901 shares of the medical instruments supplier’s stock valued at $737,000 after purchasing an additional 45,096 shares in the last quarter. Swiss National Bank lifted its position in shares of ConforMIS by 59.2% during the second quarter. Swiss National Bank now owns 53,500 shares of the medical instruments supplier’s stock valued at $230,000 after purchasing an additional 19,900 shares in the last quarter. Wells Fargo & Company MN lifted its position in shares of ConforMIS by 2.0% during the second quarter. Wells Fargo & Company MN now owns 55,021 shares of the medical instruments supplier’s stock valued at $236,000 after purchasing an additional 1,091 shares in the last quarter. Finally, Alliancebernstein L.P. lifted its position in shares of ConforMIS by 31.1% during the second quarter. Alliancebernstein L.P. now owns 40,000 shares of the medical instruments supplier’s stock valued at $172,000 after purchasing an additional 9,500 shares in the last quarter. Hedge funds and other institutional investors own 35.57% of the company’s stock.

Shares of ConforMIS (NASDAQ:CFMS) opened at $2.33 on Friday. ConforMIS has a 12-month low of $2.21 and a 12-month high of $8.61. The company has a debt-to-equity ratio of 0.52, a quick ratio of 5.38 and a current ratio of 6.19. The firm has a market cap of $110.06, a price-to-earnings ratio of -1.74 and a beta of 2.21.

ConforMIS (NASDAQ:CFMS) last posted its quarterly earnings data on Wednesday, November 1st. The medical instruments supplier reported ($0.29) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.32) by $0.03. The company had revenue of $18.40 million during the quarter, compared to analysts’ expectations of $17.55 million. ConforMIS had a negative net margin of 72.70% and a negative return on equity of 76.88%. ConforMIS’s revenue for the quarter was down 1.3% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.31) earnings per share. research analysts anticipate that ConforMIS will post -1.27 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This news story was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another publication, it was illegally copied and reposted in violation of United States & international trademark and copyright laws. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2018/01/19/conformis-inc-cfms-given-average-recommendation-of-hold-by-analysts.html.

About ConforMIS

ConforMIS, Inc is a medical technology company. The Company uses its iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants, which are individually sized and shaped, to fit each patient’s anatomy. The Company’s iFit technology platform is applicable to various joints.

Analyst Recommendations for ConforMIS (NASDAQ:CFMS)

Receive News & Ratings for ConforMIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ConforMIS and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply